Google DeepMind spinoff to test AI-designed drug this year

If you're seeing this message, that means JavaScript has been disabled on your browser.Please enable JavaScript to make this website work.

NewsPremium

👩‍🍳 How we use AI at Tech in Asia, thoughtfully and responsibly.
🧔‍♂️ A friendly human may check it before it goes live. More news here

Google DeepMind spinoff to test AI-designed drug this year

Add TIA as a preferred source

Isomorphic Labs, a spinoff of Google DeepMind, plans to begin trials for AI-designed drugs in 2025.

The company aims to drastically reduce the time it takes to discover new drugs, potentially shortening the process from a decade to just weeks or months.

Despite the potential of AI in drug development, many pharmaceutical companies remain cautious about its effectiveness.

Founded in 2021 by Alphabet, Isomorphic Labs utilizes DeepMind’s AlphaFold tool for modeling molecular structures.

Stay ahead in Asia’s tech landscape

You've reached your 2 free content limit for the month. Sign up for free to read the full story.

🏄 For casual readers / 👶 Free

Basic

US$0

Free forever

Get instant access to this article and more every month

0 premium content

Unlimited news briefs

5 articles

Ad-free reading experience

Just US$0 per day

⌛Sign up in 20s. No payment details needed.

📖 For learners / 👍 Starter

Lite

US$4.92/month

Billed annually at US$59/year

Get instant access to this article and more every month

4 premium content

Unlimited news briefs & articles

Ad-free reading experience

Just US$0.17 per day

Cancel anytime

Our subscriber community includes professionals from these companies:

Stay ahead in Asia’s tech landscape

Stay updated on the go with our mobile app.